SCHEMBL22042930

SCHEMBL22042930

O=C(CCl)Nc1cc(Br)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
HPGD P15428 5/20 0.49
RAB9A P51151 5/20 0.49
LMNA P02545 3/20 0.49
MAPT P10636 3/20 0.49
HTT P42858 3/20 0.48
NPC1 O15118 2/20 0.48
ALDH1A1 P00352 4/20 0.46
PAX8 Q06710 1/20 0.45
HDAC1 Q13547 1/20 0.44
KDM4E B2RXH2 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALOX15 P16050 2/20 0.43
CES2 O00748 1/20 0.43
GALR3 O60755 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30612623 1.00 POLB (0.50) POLBMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL3755148 0.82 POLB (0.53) POLBMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL29914686 0.82 POLB (0.53) POLBMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL247350 0.81 POLB (0.75) POLBMEN1KMT2AHPGDLMNA
SCHEMBL21409465 0.81 MITF (0.51) POLBMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL30612630 0.81 POLB (0.75) POLBMEN1KMT2AHPGDLMNA
SCHEMBL10603799 0.81 NPC1 (0.57) MEN1KMT2ASMN1; SMN2HPGDRAB9A
SCHEMBL30613082 0.81 NPC1 (0.57) MEN1KMT2ASMN1; SMN2HPGDRAB9A
SCHEMBL25401909 0.80 GAA (0.50) POLBMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL16858580 0.79 POLB (0.50) POLBMEN1KMT2ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195469-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-01-14 US disclosed
EP-3892623-B1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RES INST CHEMICAL TECH (KR) 2024-07-10 EP disclosed
CN-113166161-B Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof 韩国化学研究院 2023-10-27 CN disclosed
US-20220024932-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-27 US disclosed
US-20220024932-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-27 US disclosed
EP-3892623-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF Korea Research Institute of Chemical Technology (KR) 2021-10-13 EP disclosed
CN-113166161-A Compound with PDE9A inhibitory activity and pharmaceutical use thereof 韩国化学研究院 2021-07-23 CN disclosed
WO-2020116971-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF 한국화학연구원 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195469-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof PDE9A, PDE5A, PDE3A POLB 3019/4885MEN1 2770/4885KMT2A 1360/4885
US-20220024932-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF PDE9A, PDE5A, PDE3A POLB 3019/4885MEN1 2770/4885KMT2A 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.